Exalpha Biologicals, Inc.

Upcoming Meetings

7th International Ceramide Conference

Oct. 20-24, 2013

Montauk, Long Island, New York

Learn More

13th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases

November 3 - 6, 2013

San Juan, Puerto Rico

Learn More

Latest References

Luo Z, Luo P, Yu Y, Zhao Q, Zhao X, Cheng L. "SPARC promotes the development of erythroid progenitors." Exp Hematol. 2012 Jun 9

Learn More

Basu, G., et al. "Frequency distribution of SPARC in triple-negative breast cancer patients." J. Clin. Oncol., 29, 2011 (suppl 27; abstr 37)

Learn More

PINK1 (E417G Mutant)

  • Product Code: X2778B
  • Size: 50 µg
  • Availability: In Stock In Stock
  • Price (USD): $110

Cat #

X2778B		 Quantity:      

Data Sheet

Product Name

PINK1 (E417G Mutant)

Synonyms

PTEN-induced putative kinase protein 1

Product Type

Blocking Peptide

Reactivity

Blocking Peptide to Cat # X2763P

Applications

Blocking Peptide

Size

50 µg

Price (USD)

$110

Background

This peptide is the immunogen used to make Cat # X2763P. Protects against mitochondrial dysfunction during cellular stress, potentially by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy). It is necessary for PARK2 recruitment to dysfunctional mitochondria to initiate their degradation. Defects in PINK1 are the cause of Parkinson disease type 6 (PARK6). A neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep.

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles